17.11.2016 • NewsElaine BurridgeMylanepipen

US Senator Urges DoJ to Testify at EpiPen Hearing

(c) Mylan
(c) Mylan

US Senator Chuck Grassley, chairman of the Judiciary Committee, is urging the Department of Justice (DoJ) to reconsider its decision to refuse to appear voluntarily at a Judiciary Committee hearing on issues related to Mylan’s EpiPen’s reported misclassification with public health insurer Medicaid and resulting overcharges to taxpayers. Grassley has scheduled a hearing for Nov. 30 to examine a potential settlement in reported overcharges under the Medicaid Drug Rebate Program and the role government agencies had in the misclassification.

“Accountability requires getting answers about why the overcharges happened and what, if anything, is being done to make sure the taxpayers are repaid for their losses and to keep this from happening again,” he said. In response, the DoJ said as per longstanding practise, it “declines requests for non-public information about pending matters and investigations.”

Mylan Pharmaceuticals announced a settlement with the US government of $465 million on Oct. 7, and also confirmed during its third-quarter earnings call on Nov. 9 that it was working to finalize the deal. However, the DoJ has said there is no “executed settlement” so far. The deal has come under criticism from some officials who want the DoJ to ask for more. Senator Richard Blumenthal called it a “shadow of what it should be”, while West Virginia Attorney General Patrick Morrisey described it as a “sweetheart” deal.

The money that Mylan has set aside to end the dispute contributed to its third-quarter net loss of nearly $120 million, compared to a profit of nearly $429 million in the same period a year earlier. The drugmaker said in August it is planning to launch an authorized generic of its EpiPen at half the price, expected in the first half of December.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.